Blue Owl Capital Holdings LP Takes $3 Million Position in Palvella Therapeutics (NASDAQ:PVLA)

Blue Owl Capital Holdings LP bought a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 250,062 shares of the company's stock, valued at approximately $3,001,000. Palvella Therapeutics makes up 0.7% of Blue Owl Capital Holdings LP's portfolio, making the stock its 27th biggest holding. Blue Owl Capital Holdings LP owned approximately 2.23% of Palvella Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter worth approximately $171,000. Renaissance Technologies LLC acquired a new position in Palvella Therapeutics during the 4th quarter worth $256,000. BML Capital Management LLC acquired a new position in Palvella Therapeutics during the 4th quarter worth $506,000. Finally, ADAR1 Capital Management LLC acquired a new position in Palvella Therapeutics during the 4th quarter worth $1,736,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 2,500 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the acquisition, the director now directly owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This trade represents a 1.38 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.39% of the company's stock.

Palvella Therapeutics Stock Up 2.0 %

Shares of Palvella Therapeutics stock traded up $0.50 on Tuesday, hitting $25.07. 107,809 shares of the company's stock traded hands, compared to its average volume of 69,818. The firm has a 50-day moving average price of $24.18. The company has a market cap of $276.25 million, a PE ratio of -2.07 and a beta of 0.10. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.

Analyst Upgrades and Downgrades

PVLA has been the topic of several research reports. Stifel Nicolaus initiated coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They set a "buy" rating and a $45.00 price objective on the stock. Jones Trading initiated coverage on Palvella Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $45.00 price objective on the stock. TD Cowen initiated coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They set a "buy" rating and a $44.00 price objective on the stock. Scotiabank initiated coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $44.43.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.